Rigel Pharmaceuticals

Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing, and providing novel small-molecule drugs that significantly improve the lives of patients with hematologic disorders and cancer. Rigel's commercial products include TAVALISSE (fostamatinib disodium hexahydrate) for the treatment of thrombocytopenia in adults with chronic immune thrombocytopenia, REZLIDHIA (olutasidenib) for relapsed or refractory acute myeloid leukemia with IDH1 mutations, and Gavreto (pralsetinib) for certain RET-altered non-small cell lung cancers. The company is headquartered in South San Francisco, California.